Equities analysts expect Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) to post $38.96 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Tabula Rasa Healthcare’s earnings, with the highest sales estimate coming in at $39.11 million and the lowest estimate coming in at $38.80 million. Tabula Rasa Healthcare posted sales of $27.31 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 42.7%. The firm is scheduled to issue its next earnings report on Monday, March 12th.
On average, analysts expect that Tabula Rasa Healthcare will report full year sales of $38.96 million for the current year, with estimates ranging from $127.30 million to $129.72 million. For the next financial year, analysts anticipate that the company will post sales of $179.45 million per share, with estimates ranging from $174.90 million to $182.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Tabula Rasa Healthcare.
Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Tabula Rasa Healthcare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The business had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. During the same quarter in the previous year, the firm posted $0.06 EPS. The firm’s revenue was up 37.6% on a year-over-year basis.
TRHC has been the subject of a number of research analyst reports. UBS AG lifted their target price on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Chardan Capital lifted their target price on shares of Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $29.00 target price on shares of Tabula Rasa Healthcare in a research report on Tuesday, October 24th. ValuEngine raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Zacks Investment Research downgraded shares of Tabula Rasa Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 10th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $28.25.
TRADEMARK VIOLATION WARNING: This story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/11/23/38-96-million-in-sales-expected-for-tabula-rasa-healthcare-inc-trhc-this-quarter.html.
In other news, insider Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 45.80% of the company’s stock.
Hedge funds have recently modified their holdings of the company. TIAA CREF Investment Management LLC grew its position in shares of Tabula Rasa Healthcare by 108.5% during the 1st quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after acquiring an additional 4,232 shares during the period. Financial Consulate Inc. bought a new position in Tabula Rasa Healthcare in the 3rd quarter worth $222,000. Rhumbline Advisers bought a new position in Tabula Rasa Healthcare in the 3rd quarter worth $253,000. California Public Employees Retirement System bought a new position in Tabula Rasa Healthcare in the 3rd quarter worth $254,000. Finally, New York State Common Retirement Fund boosted its holdings in Tabula Rasa Healthcare by 257.0% in the 2nd quarter. New York State Common Retirement Fund now owns 10,000 shares of the company’s stock worth $151,000 after buying an additional 7,199 shares during the period. 28.41% of the stock is owned by hedge funds and other institutional investors.
Shares of Tabula Rasa Healthcare (NASDAQ:TRHC) opened at $35.46 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. Tabula Rasa Healthcare has a 1 year low of $11.35 and a 1 year high of $36.60.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.